ArticlePLoS computational biology2025
RIDDEN: Data-driven inference of receptor activity from transcriptomic data.
Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Maternal Opioids Downregulate Adiponectin Receptor Signaling and Alter Growth in Offspring: Pilot Study.medRxiv : the preprint server for health sciences · 2026Article
- OmniPath: integrated knowledgebase for multi-omics analysis.Nucleic acids research · 2026Article
- Maternal opioids downregulate adiponectin receptor signaling and alter growth in offspring: pilot study.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Intracellular signaling initiated from ligand-bound receptors plays a fundamental role in both physiological regulation and development of disease states, making receptors one of the most frequent drug targets. Systems level analysis of receptor activity can help to identify cell and disease type-specific receptor activity alterations. While several computational methods have been developed to analyze ligand-receptor interactions based on transcriptomics data, none of them focuses directly on the receptor side of these interactions. Also, most of the methods use directly the expression of ligands and receptors to infer active interaction, while co-expression of genes does not necessarily indicate functional interactions or activated state. To address these problems, we developed RIDDEN (Receptor actIvity Data Driven inferENce), a computational tool, which predicts receptor activities from the receptor-regulated gene expression profiles, and not from the expressions of ligand and receptor genes. We collected 14463 perturbation gene expression profiles for 229 different receptors. Using these data, we trained the RIDDEN model, which can effectively predict receptor activity for new bulk and single-cell transcriptomics datasets. We validated RIDDEN's performance on independent in vitro and in vivo receptor perturbation data, showing that RIDDEN's model weights correspond to known regulatory interactions between receptors and transcription factors, and that predicted receptor activities correlate with receptor and ligand expressions in in vivo datasets. We also show that RIDDEN can be used to identify mechanistic biomarkers in an immune checkpoint blockade-treated cancer patient cohort. RIDDEN, the largest transcriptomics-based receptor activity inference model, can be used to identify cell populations with altered receptor activity and, in turn, foster the study of cell-cell communication using transcriptomics data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.